418
Participants
Start Date
May 2, 2018
Primary Completion Date
November 30, 2025
Study Completion Date
April 30, 2026
Icosapent Ethyl
Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
Placebo
"Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:~Dose: 4 capsules per day"
Oxford University Hospital NHS Foundation Trust, Oxford
Hampshire Hospitals NHS Foundation Trust, Basingstoke
Aintree University Hospitals NHS Foundation Trust, Aintree
University Hospitals Birmingham NHS Foundation Trust, Birmingham
Cambridge UniversityHospitals NHS Foundation Trust, Cambridge
University Hospital of Wales, Cardiff
Leeds Teaching Hospitals NHS Foundation Trust, Leeds
King's College London, London
Royal Free London NHS Foundation Trust, London
Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle
Nottingham University Hospitals NHS Trust, Nottingham
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
University Hospital Southampton NHS Foundation Trust, Southampton
Collaborators (1)
Yorkshire Cancer Research
OTHER
Amarin Pharma Inc.
INDUSTRY
Mark A Hull, PhD FRCP
OTHER